What compounds target CDK9?

BiohacksAI has identified 45 compounds that interact with CDK9 (cyclin dependent kinase 9). Top compounds include: seliciclib, alvocidib, foretinib, palbociclib, dinaciclib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is CDK9 (cyclin dependent kinase)?

CDK9 is cyclin dependent kinase 9. It is a molecular target for 45 compounds documented in PubMed bioassay data. NCBI Gene ID: 1025.

CDK9

MOLECULAR TARGET

cyclin dependent kinase 9

NCBI Gene: 102545 compounds

CDK9 (cyclin dependent kinase 9) is targeted by 45 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CDK9

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	seliciclib	4.91	135
2	alvocidib	4.52	91
3	foretinib	4.34	76
4	palbociclib	4.22	67
5	dinaciclib	3.87	47
6	molibresib	3.81	44
7	abemaciclib	3.66	38
8	fasudil	3.66	38
9	wogonin	3.61	36
10	bms 387032	3.47	31
11	fedratinib	3.40	29
12	linifanib	3.33	27
13	at 7519	3.33	27
14	ribociclib	3.26	25
15	sulfuretin	3.14	22
16	jnj 7706621	3.09	21
17	at 9283	3.09	21
18	lestaurtinib	3.04	20
19	pacritinib	3.04	20
20	momelotinib	2.89	17
21	pf 00562271	2.77	15
22	pha 665752	2.71	14
23	crenolanib	2.71	14
24	bms 345541	2.71	14
25	azd 5438	2.71	14
26	ast 487	2.56	12
27	zotiraciclib	2.56	12
28	atuveciclib	2.56	12
29	roniciclib	2.56	12
30	defactinib	2.48	11
31	ripasudil	2.40	10
32	decernotinib	2.20	8
33	y 39983	2.20	8
34	ct 7001	2.20	8
35	cyc 116	2.08	7
36	enzastaurin	2.08	7
37	rg 547	2.08	7
38	zemirciclib	2.08	7
39	istisociclib	2.08	7
40	sel 120 free base	1.95	6
41	s roscovitine	1.95	6
42	cyc 065	1.95	6
43	meriolin 1	1.95	6
44	voruciclib	1.79	5
45	alsterpaullone	0.69	1

About CDK9 as a Drug Target

CDK9 (cyclin dependent kinase 9) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 45 compounds with documented CDK9 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CDK9 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.